Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

Ilir AgalliuRoberto A OrtegaMarta San LucianoAnat MirelmanClaustre Pont-SunyerKathrin BrockmannDolores VilasEduardo TolosaDaniela BergBjørg WarøAmanda GlickmanDeborah RaymondRivka InzelbergJavier Ruiz-MartinezElisabet MondragonEitan FriedmanSharon Hassin-BaerRoy N AlcalayHelen Mejia-SantanaJan AaslyTatiana ForoudKaren MarderNir GiladiSusan BressmanRachel Saunders-Pullman

Published in: Movement disorders : official journal of the Movement Disorder Society (2019)

The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers. © 2019 International Parkinson and Movement Disorder Society.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
acute myeloid leukemia
bone marrow
climate change